May 14 |
Adicet Bio GAAP EPS of -$0.35
|
May 14 |
Adicet Reports First Quarter 2024 Financial Results and Provides Business Updates
|
May 14 |
Adicet Bio Announces Poster Presentation of ADI-270 Preclinical Data at the 2024 European Hematology Association (EHA) Hybrid Congress
|
May 7 |
Adicet Bio to Participate in a Fireside Chat at the Citizens JMP Life Sciences Conference
|
Apr 30 |
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
|
Apr 22 |
Adicet Bio Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
|
Apr 8 |
Adicet Bio to Participate in 2024 Canaccord Genuity Horizons in Oncology Virtual Conference
|
Mar 21 |
Are Investors Undervaluing Adicet Bio, Inc. (NASDAQ:ACET) By 41%?
|
Mar 19 |
Adicet Bio: Q4 Earnings Insights
|
Mar 19 |
Adicet Bio GAAP EPS of -$0.69 beats by $0.01
|